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Radiation-induced destruction of the hematopoietic sys-
tem is the primary cause of death based on the ﬁndings
that transfer of normal bone marrow cells prevents death
from lethal irradiation. The stem cell factor-c-kit signal-
ing pathway (SCF/c-kit) has been previously implicated in
the hematopoietic recovery which prevents death from
lethal irradiation, but the molecular mechanisms that
mediate this biological effect are unknown. Since muta-
tions on SCF, c-kit and Slug genes have a similar
phenotype in mice, we examined if Slug could complement
the radiosensitivity of kit-deﬁcient mice. In this report, we
show that Slug acts as a radioprotection agent as lack of
Slug results in increased radiosensitivity. This effect
cannot be recovered by activating SCF/c-kit in lethally
irradiated Slug-deﬁcient mice, as SCF-treated mice did
not demonstrate stimulation of hematopoietic recovery
leading to survival of the Slug-deﬁcient mice. We found
that we could complement the hematopoietic failure in
lethally irradiated c-kit-deﬁcient mice by transducing
them with a TAT-Slug protein. We conclude that the
zinc-ﬁnger transcription factor Slug is absolutely neces-
sary for survival from lethal irradiation and identify Slug
as the molecular target that mediates the radioprotection
through SCF/c-kit. These results indicate that Slug may
be a molecular component conferring radioresistance to
cancer cells.
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Introduction
Stem cell factor (SCF) is the product of the steel (Sl)
locus of the mouse and is the ligand for the c-kit tyrosine
kinase receptor encoded by the white spotting (W) locus
of the mouse (Sarvella and Russell, 1956; Russell, 1979;
Silvers, 1979; Chabot et al., 1988; Geissler et al., 1988;
Copeland et al., 1990; Huang et al., 1990; Martin et al.,
1990; Williams et al., 1990; Zsebo et al., 1990). The c-kit
ligand appears to have unique and nonredundant
activities on primitive progenitor cells (Witte, 1990). In
this regard, there is ample evidence that SCF, in the
absence of other cytokines, selectively promotes viability
rather than proliferation of primitive murine hemato-
poietic progenitor cells (Fleming et al., 1993). However,
the molecular mechanisms that provide biological
speciﬁcity to the SCF/c-kit signaling pathway in the
formation and migration of c-kit+ cells are largely
unknown. Recently, we have shown that Slug-mutant
mice have phenotypic characteristics similar to Sl and W
mutant mice and identiﬁed that the zinc-ﬁnger tran-
scription factor Slug is a molecular target that con-
tributes to the biological speciﬁcity of the SCF/c-kit
signaling pathway (Perez-Losada et al., 2002). Kit and
Slug genes coordinately modulate the development and
survival of melanocyte and hematopoietic lineages in
compound-deﬁcient mice (Perez-Losada et al., 2002;
Sanchez-Martin et al., 2002).
The biological properties of SCF have demonstrated
that the action of SCF is on very primitive cell
populations. In this regard, endogenous production of
SCF is required for survival from lethal irradiation
(Neta et al., 1993; Zsebo et al., 1993). Survival after
irradiation with a dose lethal (LD100/30, radiation dose
lethal to 100% of mice in 30 days) is based on recovery
of impaired hematopoietic function as transplantation
of normal bone marrow cells into lethally irradiated
animals and humans results in long-term survival and
provides proof that the hematopoietic system is crucial
for defense against the lethal complications induced by
radiation. Sl mutant animals have an LD100 of 200–
300 rad, in contrast to an LD100 of their congenic
counterparts being in the range of 720––900 rad
(Harrison and Russell, 1972; Kaczmarek et al., 1988),
showing that lack of SCF results in increased radio-
sensitivity. Since mutations on SCF, c-kit, and Slug
genes have a similar phenotype that affects hematopoi-
esis (Perez-Losada et al., 2002), and the radiosensitivity
is a characteristic phenotypic abnormality seen in Sl and
W mutants in vivo (Harrison and Russell, 1972;
Kaczmarek et al., 1988), we examined if Slug could
complement the radiosensitivity of kit-deﬁcient mice.
Here we show that lack of Slug results in increased
radiosensitivity and this effect cannot be recovered by
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treating lethally irradiated Slug-mutant mice with SCF
stimulation of hematopoietic recovery. In contrast, we
could complement the hematopoietic failure following
DNA damage after g-irradiation in c-kit-deﬁcient mice
by transducing them with a TAT-slugh protein. These
results probe that the radioresistance biological function
of SCF is mediated by the zinc-ﬁnger transcription
factor Slug.
Results
Radioprotective potential of Slug-deficient cells in
response to g-irradiation
Slug-deﬁcient bone marrow cells were analysed func-
tionally in vivo after DNA damage induced by g-
irradiation. Initially, Slug +/+, +/ and / mice
were irradiated at various doses ranging from 100 to
1200 rad (1 rad¼ 0.01Gy) to determine an LD of
irradiation for the Slug mice used in these studies. A
total of 50% of mice survived for 30 days given an
irradiation dose of 275 rad (LD50/30). Similarly, the
LD90/30 was obtained at 300 rad, and the LD100/30 was
obtained at 350 rad (Figure 1). Thus, Slug / mice had
an LD100/30 of 350 rad in contrast to an LD100/30 of their
Slug +/+ congenic counterparts being in the range of
1100–1150 rad. Subsequent studies were therefore per-
formed at 350 rad to obtain a lethal dose of irradiation
for Slug-deﬁcient mice.
As the heterozygous loss-of-function of Slug leads to
phenotypic abnormalities (Perez-Losada et al., 2002;
Sanchez-Martin et al., 2002), we also determine the LD
of irradiation for the Slug +/ mice. The LD100/30 of
Slug +/ mice was obtained at 1100 rad (Figure 1),
being similar to the LD 100/30 of their Slug +/+
congenic counterparts. These results indicate that a loss-
of-function mutation of Slug in one allele does not result
in increased radiosensitivity.
To determine if hematopoietic recovery was crucial in
the recovery from these doses of irradiation, Slug /
and +/ mice irradiated at 350 and 1100 rad,
respectively, were transplanted with bone marrow cells
from syngeneic normal donors. At 4 h postirradiation,
i.v. injection of bone marrow resulted in 100% survival
of mice at both doses of irradiation compared to 0%
survival of control animals that did not receive a bone
marrow transplant (BMT). The serum chemistry data
showed no signiﬁcant differences, suggesting that there
were no major organ failures that could account for the
differences in survival in the groups. Blood cultures of
peripheral blood detected the presence of gut-related
bacteria in 10 of 10 mice which did not recieve a BMT
compared to none of nine BMT-treated mice.
Normal p53 activation in Slug-deficient bone marrow
(BM) cells in response to DNA damage
We have found that Slug-deﬁcient BM cells are radio-
sensitive to DNA damage induced by g-irradiation. p53
is centrally involved in the cellular response to radiation
(Lee et al., 1994). Exposure to ionizing radiation causes
an increase in the intracellular levels of p53 (Kastan
et al., 1991). Thus, we next explored if the radio-
protective potential of Slug was based on interference
with p53 activation. As shown in Figure 2, we measured
the p53 protein levels at different time points in BM cells
derived from both Slug / and Slug +/+ mice after
DNA damage induced by g-irradiation. The activation
of p53 in both control and Slug-deﬁcient cells was
similar (Figure 2), indicating that p53 regulation in
response to DNA damage is not affected in Slug-
deﬁcient cells. These results are in agreement with
previous data (Inoue et al., 2002) and suggest that Slug
does not require p53 for its radioprotective function.
Role of SCF on hematopoietic recovery in lethally
irradiated Slug-deficient mice
Radioprotective potential was found only in wild-type
BM whereas Slug-deﬁcient BM did not protect from
lethal irradiation. The radioprotective potential in mice
is subject to modulation by SCF/c-kit interactions
(reviewed by Broudy, 1997). Treatment of irradiated
mice with SCF results in increased survival compared to
irradiated controls (Neta et al., 1993; Zsebo et al., 1993).
Since SCF radioprotection is manifest both after i.p.
and i.v. routes of injection for rSCF in mice (Zsebo et al.,
Figure 1 Effect of irradiation on survival of Slug / mice. Slug
/ and +/ mice were irradiated at various doses to determine a
lethal dose of irradiation. The survival of Slug +/ and wild-type
(wt) mice was not inﬂuenced by irradiation at low doses. The
radiation dose was given as a split dose of equal intensity, 4 h apart
Figure 2 Levels of p53 protein in BM cells after g-irradiation. p53
protein was detected by Western blotting in Slug +/+ and Slug
/ BM cells. Actin was used as a loading control. The time
points are in hours
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1993), the i.v. route was used in our experiments. The
combination of pre and post-treatment with SCF (20,
2, and +4h) results in 100% survival of Slug +/+
and +/ mice irradiated at 1100 rad (Table 1).
To determine the extent to which SCF could protect
Slug / mice against otherwise lethal irradiation, Slug
/ mice were irradiated at 350 rad and injected with
SCF or carrier. By day 30, 0% of Slug / animals
survived. In comparison, none of the SCF-treated Slug
+/+ and +/ animals died postirradiation, and the
animals continued to survive past the 30-day study
period. The BM cellularity, including CFU-GM, CFU-
E, and BFU-E, never recovered in Slug / SCF-
treated mice (Figure 3). By day 3 postirradiation, the
BM cellularity dropped toB4% of preirradiation levels
(Figure 3), whereas Slug +/ SCF-treated mice had a
dramatic increase in cellularity by day 8 and had almost
returned to preirradiation levels by day 21 (Figure 3).
These results were concordant with peripheral blood
hematology which showed no signiﬁcant differences
between SCF-treated and untreated Slug / mice
(Perez-Losada et al., 2002) and we did not observe the
expected increase in WBCs, RBCs, and platelet values
during the 2–3 weeks postirradiation.
Rescue of aplasia induced by lethal irradiation in
kit-mutant mice by TAT-Slug
Slug is a downstream molecular target of the SCF/c-kit
signaling pathway (Perez-Losada et al., 2002), thus we
next explored if Slug could defend against the hemato-
poietic failure induced by radiation in kit-mutant mice.
As there were no pharmacological mechanisms to
activate Slug, we turned to the transduction of Slug:
TAT-Slug (Figure 4a). An amino-terminal TAT-Slug
protein was generated (Nagahara et al., 1998). Immu-
noblot and microscopic analysis revealed that the TAT-
Slug fusion protein was rapidly transduced into cultured
cells reaching near maximum intracellular concentra-
tions in less than 20min (Figure 4b–d).
We next intraperitoneally (i.p.) injected TAT-Slug
protein into Slug / mice (Schwarze et al., 1999).
Immunoblot analysis of BM cells isolated 120min after
i.p. injection demonstrated the presence of TAT-Slug
protein reaching maximum concentrations after injec-
tion of 250 mg of TAT-Slug fusion protein (Figure 4e).
To test the effect of TAT-Slug in lethally irradiated
Slug-deﬁcient mice, we administrated a single dose of
250 mg of TAT-Slug protein immediately after lethal
irradiation. All 10 Slug-deﬁcient mice survived after
treatment with the TAT-Slug protein compared with
none of 10 Slug-deﬁcient mice treated with TAT-control
protein (Figure 4f). These results demonstrate that the
administration of TAT-Slug can completely comple-
ment the recovery from aplasia induced by lethal
irradiation in Slug-deﬁcient mice.
We next test the effect of TAT-Slug in irradiated kit-
deﬁcient mice by administration of a single dose of
250 mg of the TAT-Slug protein immediately after lethal
irradiation. All 10 kit-deﬁcient mice survived after
tretament with the TAT-Slugh protein compared with
none of 10 kit-deﬁcient mice treated with TAT-control
protein (Figure 4f). The TAT-Slugh protein protected
kit-deﬁcient BM cells from apoptosis after lethal
irradiation (Figure 5a). The bone marrow cellularity of
kit-deﬁcient TAT-Slug-treated mice recovered and al-
most returned to preirradiation levels and these results
were concordant with peripheral blood hematology
(Figure 5B). Thus, TAT-Slug appears to protect kit
mutant mice from lethal irradiation, indicating that Slug
mediates the radioprotective potential of the kit/SCF
signaling pathway.
Discussion
The radioprotective function of the SCF/c-kit signaling
pathway is mediated by Slug
The biological events controlled by the SCF/c-kit
signaling pathway are implicated in the generation and
migration of hematopoietic stem cells (Witte, 1990;
Fleming, 1993). In this study, we have investigated if the
survival from lethal irradiation governed by the SCF/c-
kit signaling pathway is mediated by the Slug transcrip-
tion factor. Accordingly, as the absence of Slug impairs
Table 1 Effect of SCF on survival of LD100/30 irradiated mice
Genotype Treatment Dead/total % survival
Slug/ Excipient 40/40 0
Slug/ SCF 40/40 0
Slug+/ Excipient 40/40 0
Slug+/ SCF 0/40 100
Slug+/+ Excipient 40/40 0
Slug+/+ SCF 0/40 100
The excipient or the SCF was injected i.v. at 20 and 2 h prior to
irradiation and 4 h after the last dose of irradiation. Slug / were
irradiated at 350 rad and Slug +/ and +/+ at 1.100 rad
Figure 3 Bone marrow cellularity of mice irradiated at LD100/30
and treated with SCF. The SCF was injected i.v. at 20 and 2 h prior
to irradiation and 4 h after the last dose of irradiation. The BM
cellularity of wt mice was similar to Slug +/ mice irradiated at
LD100/30 and treated with SCF. Data presented are the mean7
s.e.m. for four mice at each time point
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the development of hematopoietic stem cells (Perez-
Losada et al., 2002) and mutations at either W or Sl, and
Kit and Slug genes coordinately modulate the develop-
ment and survival of melanocyte and hematopoietic
lineages in compound-deﬁcient mice (Perez-Losada
et al., 2002; Sanchez-Martin et al., 2002), we ﬁrst
analysed if the absence of Slug results in increased
radiosensitivity. The data presented in this study clearly
demonstrate that mice mutated at the Slug locus are
radiosensitive. These results corroborate that Slug is
absolutely necessary for survival from lethal irradiation
of unmanipulated mice (Inoue et al., 2002). As Slug-
mutant mice have a normal SCF/c-kit signaling pathway
(Perez-Losada et al., 2002), we further demonstrate that
the activation of c-kit by SCF speciﬁcally cannot recover
this effect in Slug-mutant mice. In contrast, we could
complement the hematopoietic failure following DNA
damage after g-irradiation in c-kit-deﬁcient mice by
transducing them with a TAT-Slug protein, showing
that the SCF stimulation of hematopoietic recovery
after lethal irradiation is mediated by Slug.
These ﬁndings are congruent with our proposed
model in which stem cells harboring the c-kit receptor
would express Slug, promoting survival of the cell, with
dependence of the required external signal (SCF) and
allowing cells to migrate outside their normal environ-
ment. If this is not achieved in a speciﬁc period of time,
they would undergo apoptosis as they have been
deprived of required external signals to keep Slug
expression (Perez-Losada et al., 2002).
Importance of the Slug-dependent radioresistance in
cancer therapy
Our results show that the radioresistance confers to
HSC cells by SCF/kit signaling pathway is mediated by
Slug. The c-kit receptor is involved in both leukemias
and solid tumors. Mutations resulting in constitutive
activation of c-kit have been described in acute myeloid
leukemias (Furitsu et al., 1993; Nagata et al., 1995),
small cell lung cancer (Matsuda et al., 1993), gynecolo-
gical tumors (Inoue et al., 1994), breast carcinomas
(Hines et al., 1995) and colonic tumors derived from
intersticial cells of Cajal (a cell type that is SCF
dependent) (Hirota et al., 1998; Nishida et al., 1998).
Thus, constitutive activation of c-kit could confer
radioresistance properties to the tumor cells. Moreover,
recent ﬁndings show that Slug is also expressed in
t(17;19) leukemic cells (Inukai et al., 1999), in rhabdo-
myosarcoma cells expressing the translocation PAX3-
FKHR (Khan et al., 1999), and in cells expressing BCR-
ABL (JPL et al., unpublished observations). Thus, Slug
may be a common component providing radioresistance
to tumor cells. As such, Slug might therefore constitute
an attractive target in the treatment of human cancer.
Figure 4 Transduction of TAT-Slugh into mice. (a) Diagram of TAT-Slug fusion. (b) Immunoﬂuorescence of untransduced Ba/F3
cells (left panel) and Ba/F3 cells transduced with TAT-Slug protein. TAT-Slug protein was detected with the 12CA5 monoclonal
antibody, which detects the HA epitope. (c) Immunoblot of Ba/F3 cells 60min after being transduced with different amounts of TAT-
Slug protein. (d) Immunoblot of Ba/F3 cells transduced with 50 mg of TAT-Slug protein at different time points. (e) Immunoblot of
BM cells isolated from Slug /mice 120min after i.p. injection of different amounts of TAT-Slug fusion protein. (f) Effect of
irradiation on survival of kit-deﬁcient mice transduced with TAT-Slug fusion protein. Mice were irradiated at 350 rad given as a split
dose. SCF was injected i.v. at 20 and 2 h prior to irradiation and 4 h after the last dose of irradiation and TAT proteins were injected
i.p. with a single dose of 250mg immediately after irradiation
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In this sense, Slug has been shown to play similar
roles to Snail in several systems (Cheng et al., 2001;
Blanco et al., 2002; Del Barrio and Nieto, 2002; Hajra
et al., 2002), and, thus, other members of the Snail
family of transcription factors could also be involved in
similar biological functions to those described herein to
Slug.
Methods
Mice
Mice heterozygous and homozygotes for the SlughD1 mutation
generated by removing the genomic sequences of the entire
Slugh protein-coding region (SlughD1 mutant mice) have been
previosly described (Jiang et al., 1998). W/Wv mice and
breeding pairs were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA). All the procedures were approved by
the Institutional Animal Care Committee. Mice were irra-
diated at various doses using a cesium source, given as a split
dose of equal intensity, 4 h apart. Mice were injected i.v. in the
tail vein SCF (Sigma) at a dose of 100 mg/kg or saline
containing 0.1% fetal bovine serum (excipient for SCF
dilutions) at various time intervals. All recipients were
maintained in microisolator cages on sterilized food and
acidiﬁed sterile water. The number of surviving mice was
recorded daily for 30 days.
Bone marrow analysis
Bone marrow cells (0.25–1.0 105 cells/plate) isolated from
normal and Slug-mutant mice were seeded into FBS-free
semisolid culture plates (Stem Cell Technologies). Colony
growth was stimulated with the following combinations of
recombinant growth factors: rat stem cell factor (100 ngml;
Sigma), mouse interleukin 3 (10 ngml; Sigma), and human
EPO (2U/ml; Roche) for burst-forming unit erythroid (BFU-
E) growth. The growth of colony-forming unit-erythroid
(CFU-E)-derived colonies was stimulated with EPO alone
(2U/ml). The growth of myeloid colonies (CFU-GM) was
stimulated with recombinant murine GM-CSF (10 ngml;
SIGMA) in the presence or absence of SCF (100 ngml;
Sigma). The cultures were incubated at 371C in a humidiﬁed
incubator containing 5% CO2 in air and scored either 3 days
(for CFU-E-derived colonies) or 7 days (for GM-CSF and
BFU-E-derived colonies) following initiation of the culture.
The frequency of the colonies was determined in triplicate
cultures.
Peripheral blood analysis
Peripheral blood samples were collected into EDTA-contain-
ing tubes by retro-orbital bleedings and were subjected to
automated complete blood cell counts. For blood cultures,
blood was collected in sterile 1-ml insulin syringes coated with
70 ml of a 3.8% trisodium citrate solution (used as an
anticoagulant that does not inhibit aerobic growth). An
aliquot (0.1ml) of blood was inoculated into tubes containing
(i) trypticase soy broth or (ii) ﬂuid thioglycolate medium and
incubated at 351C for 7 days, after which time the presence of
bacteria was determined using standard techniques.
Serum chemistry
Whole serum was collected without the addition of antic-
oagulants, and serum chemistry values were calculated using
Figure 5 Rescue of aplasia induced by lethal irradiation in kit-mutant mice by TAT-Slug. (a) Effect of SLUG on the survival of W/Wv
BM cells after irradiation. Cell death is accompanied by nucleosome laddering after irradiation. Low molecular weight DNA was
isolated 6 h after irradiation with 350 rad from control mice (lane 1), W/Wv mice treated with SCF – the SCF was injected i.v. at 20 and
2 h prior to irradiation and 4 h after the last dose of irradiation – lane 2, WAVv mice injected i.p. with a single dose of 250mg of TAT-
Slug fusion protein immediately after irradiation (lane 3), and W/Wv mice injected i.p. with a single dose of 250mg of TAT control
protein immediately after irradiation (lane 4). DNA was end-labeled, resolved by electrophoresis in a 2% agarose gel, and visualized by
autoradiography. (b) Peripheral blood hematology of mice irradiated at 350 rad and treated with TAT-Slug fusion protein or TAT
protein. Similar results were obtained after studying ﬁve mice per group. WBC count, platelets, RBC count, and haemoglobin (Hb)
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an automated serum chemistry analyzer (Beckman). Values for
blood urea nitrogen, potassium, glucose, albumin, total
protein, and creatinine were analysed for 10 animals per
group per day.
Transduction of TAT-Slug into mice
Slug / and kit (W/Wv) mutant mice (8-week-old) were
injected intraperitoneally with 250 mg of either TAT-Slug
fusion protein or TAT protein in 500 ml of phosphate-buffered
saline (PBS). Treated mice were irradiated and analysed as
previously described.
Genetic TAT-Slug fusion was generated by insertion of the
Slug open reading frame DNA into the pTAT-HA plasmid
(Nagahara et al., 1998) and they were then transferred into
BL21(DE3)LysS bacteria. Both TAT and TAT-Slug fusion
proteins were puriﬁed as described (Nagahara et al., 1998) by
sonication in 8M urea followed by passage over an Ni-NTA
column (Qiagen), desalted over aPD-10 column (Amersham
Pharmacia) into PBS, then ﬂash frozen in 10% glycerol and
stored at –801C.
Labelling of cells
Ba/F3 cells transduced with the TAT-Slug fusion protein were
analysed by immunoﬂuorescence labeling as follows. Cells
were ﬁxed in 4% (w/v) paraform aldehyde for 15 min, washed
in PBS, and permeabilized in methanol for 2min. After
blocking in 5% FCS in PBS for 30min, the anti-HA
monoclonal antibody (12CA5) was used to detect transduced
cells. Fluorescent cells were visualized by epiﬂuorescent
microscopy. Images were recorded on the confocal scanning
microscope.
Immunoblot
Bone marrow cells were collected by ﬂushing the marrow
cavity of femurs. Western blot assays were carried out using
extracts from 1 107 BM cells or Ba/F3 cells per lane. Mouse
p53 was detected using the anitbody FL-393 (Santa Cruz),
TAT-Slugh fusion protein was detected using the anti-HA
antibody (12CA5). The polyclonal antibody C-11 (Santa Cruz)
was used to detect actin.
DNA analysis
Low molecular weight DNA was isolated as follows. Cells
were collected into 1.5ml of culture medium and microcen-
trifuged for 1min at 1500 r.p.m (400 g), and the pellet was
suspended in 300ml of proteinase K buffer. After overnight
incubation at 551C, DNA was ethanol-precipitated, suspended
in 200ml of TE buffer containing 50mg/ml of RNase A, and
incubated at 371C for 2 h. DNA was extracted with phenol and
chloroform and precipitated with ethanol. Aliquots of DNA
(2mg) were end-labeled with a32-dCTP and electrophoresed
on 2% agarose gels. After electrophoresis, the gel was blotted
onto Hybond-N (Amersham) and autoradiographied for 2 h at
701C.
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